This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

16/100

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Inflammation and the immune system

Topic: Inflammation, microglia and astrocytes

Plain-language summary

This method establishes a platform for high-throughput longitudinal drug screening in immunocompetent human COs that will enable the identification of new therapeutic candidates to modulate Aβ aggregation, glial reactivity, and neurodegeneration. Highlights A platform was developed for high-resolution in vitro visualization of insoluble Aβ aggregates in live MCOs. The approach enables deep tissue imaging of Aβ pathology in intact 3D MCOs, allowing spatial mapping of Aβ aggregate distribution over time. Differences in Aβ burden and viability of neurons, neural progenitors, and astrocytes were quantified, distinguishing T21 COs from D21 control MCOs. The platform is positioned to support high-throughput longitudinal drug screening, providing a scalable tool to identify novel therapeutics targeting Aβ-mediated neurodegeneration.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Quang, D., Summers, R., Dooling, B. R., Esquer, H., Zhou, Q., LaBarbera, D. V., et al. (2026). High-content imaging of live microglia-containing Alzheimer’s disease brain organoids. bioRxiv. https://doi.org/10.64898/2026.10.26.761970

Vancouver

Quang D, Summers R, Dooling BR, Esquer H, Zhou Q, LaBarbera DV, et al. High-content imaging of live microglia-containing Alzheimer’s disease brain organoids. bioRxiv. 2026. doi:10.64898/2026.10.26.761970.

BibTeX

@article{quang2026-09848cb6,
  author  = {Quang, D. and Summers, R. and Dooling, B. R. and Esquer, H. and Zhou, Q. and LaBarbera, D. V. and Vergara, M. N. and Chial, H. J. and others},
  title   = {{High-content imaging of live microglia-containing Alzheimer’s disease brain organoids}},
  journal = {bioRxiv},
  year    = {2026},
  doi     = {10.64898/2026.10.26.761970},
  url     = {https://doi.org/10.64898/2026.10.26.761970}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: this is a follow-up (cohort) study. People are observed over time and not assigned to anything, so an association can reflect other differences between groups. Look at how long follow-up lasted, how many dropped out, and whether the authors adjusted for age, education and other health conditions.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded moderate. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Moderate means the abstract mentions a cohort, case-control or longitudinal design. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

This method establishes a platform for high-throughput longitudinal drug screening in immunocompetent human COs that will enable the identification of new therapeutic candidates to modulate Aβ aggregation, glial reactivity, and neurodegeneration.
Highlights A platform was developed for high-resolution in vitro visualization of insoluble Aβ aggregates in live MCOs.
The approach enables deep tissue imaging of Aβ pathology in intact 3D MCOs, allowing spatial mapping of Aβ aggregate distribution over time.
Differences in Aβ burden and viability of neurons, neural progenitors, and astrocytes were quantified, distinguishing T21 COs from D21 control MCOs.
The platform is positioned to support high-throughput longitudinal drug screening, providing a scalable tool to identify novel therapeutics targeting Aβ-mediated neurodegeneration.

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 16/100

Preprint — not yet peer-reviewed. It scored 35 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for sample size, effect reported and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 62 points we could judge it on, which is 35 out of 100.

Component	Points	Why
Journal tier	2 / 10	Tier 4 — not a peer-reviewed journal (bioRxiv)
Journal's citation record	0 / 4	Not a journal article, so the journal's record does not count
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	4 / 10	Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Laboratory or animal study (title names “organoids”) — scores zero
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	— / 7	No citation count (not found in OpenAlex) — left out of this score
Citations per year	— / 5	No citation count or no year — left out of this score
Impact for its field and year	— / 6	No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here	— / 6	Not yet checked against this library's citation graph — left out of this score
Still being cited	— / 4	No yearly citation counts — left out of this score
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multicenter collaboration	— / 3	Institutions not listed — left out of this score
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	0 / 2	Behind a paywall — scores zero
Points	22 / 62	Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 22 of the 62 points we could judge it on is 35 out of 100.
Total	35 / 100	Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Inflammation and the immune system from nearby years

Also tagged “inflammasome”

384 studies in the library carry the topic tag “inflammasome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 384 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →